Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

The PAH Initiative is hosting a video event in May to provide information about exercise benefits for PAH patients.

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...

In April 2025, Actelion announced a study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the ...